

## **Daniel Fischer**

Daniel Fischer is a Founder of Tevard Biosciences and Program Director (ILP) at the Massachusetts Institute of Technology (MIT).

Daniel co-founded Tevard Biosciences to develop gene therapy approaches to cure Dravet Syndrome and other rare diseases. Currently working on several novel gene therapy centered platforms led by a scientific team that includes: Harvey Lodish, Bob Langer, David Liu, and Orrin Devinsky.

At MIT Daniel works with industry, academic researchers, and startups in advancing the state-of-the-art in multiple disciplines, including: AI/machine learning, new materials, nanotechnology, IoT, and innovation management.

Formerly Daniel was the Director of the Epilepsy Therapy Project of the Epilepsy Foundation where he drove the development of new therapies for the epilepsies in partnership with industry and academia, and envisioned novel programs including the Epilepsy Innovation Institute (Ei2).

Daniel was President, and CEO of Intellimedix a company he founded to repurpose FDA approved drugs for Dravet Syndrome and other rare diseases using high-throughput *in silico* and zebrafish screening.

Prior to entering the biotech sector Daniel was a management consultant with several top-tier consultancies including A.T. Kearney, Arthur D. Little, and Zyman Group (with ex-Coca Cola CMO, Sergio Zyman).

Daniel lives in Newton, MA with his wife Karina and 4 children: Jonathan, David, Nicole and Natasha.